Overcoming Fear of ‘CPV Monster,’ Drug Makers Launch Continued Process Verification Programs
This article was originally published in The Gold Sheet
Most pharmaceutical manufacturers are adopting or making plans to adopt the continued process verification approach outlined in FDA’s November 2011 process validation guidance, which will shine a light on their manufacturing processes. But not everyone is anxious to see what that light will reveal.
You may also be interested in...
Biopharmaceutical manufacturers say that implementation of continued process verification has helped to update “archaic” manufacturing processes for legacy products and uncover problems with raw materials. They have reaped some business benefits as well.
If it works, the quality metrics initiative outlined in draft FDA guidance will help the global pharmaceutical supply chain prevent quality failures and drug shortages. But there will be challenges.
If it works, tracking the four quality metrics outlined in FDA guidance will help the global pharmaceutical supply chain prevent quality failures and drug shortages.